Impact BioMedical, INC. Increase (Decrease) in Prepaid Expense and Other Assets
Impact BioMedical, INC. (IBO) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$91.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-07
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$44.00K.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$47.00K.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$63.00K.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $35.00K, a 89.16% decline year-over-year.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$126.00K, a 147.55% decline from fiscal 2024.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $265.00K.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$104.00K, a 273.33% decline from fiscal 2022.
- Impact BioMedical, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $60.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$91.00K 10-Q · filed 2026-08-07 | -$154.00K derived: sum of 3 quarters · filed 2026-08-07 | -$119.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$47.00K 10-Q · filed 2026-05-12 | -$110.00K derived: sum of 2 quarters · filed 2026-05-12 | -$75.00K derived: sum of 3 quarters · filed 2026-05-12 | -$76.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$28.00K derived: sum of 2 quarters · filed 2026-03-11 | -$29.00K derived: sum of 3 quarters · filed 2026-08-07 | -$126.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $34.00K derived: sum of 2 quarters · filed 2026-08-07 | -$63.00K 10-Q · filed 2025-11-07 | -$163.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$98.00K 10-Q · filed 2026-08-07 | -$198.00K derived: sum of 3 quarters · filed 2026-08-07 | $125.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$97.00K 10-Q · filed 2026-05-12 | -$197.00K derived: sum of 2 quarters · filed 2026-05-12 | $126.00K derived: sum of 3 quarters · filed 2026-05-12 | $166.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $223.00K derived: sum of 2 quarters · filed 2026-03-11 | $263.00K derived: sum of 3 quarters · filed 2026-03-11 | $265.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $323.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $363.00K derived: sum of 2 quarters · filed 2025-11-07 | $365.00K 10-Q · filed 2025-11-07 | $269.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $42.00K 10-Q · filed 2025-08-14 | -$54.00K derived: sum of 3 quarters · filed 2025-08-14 | -$5.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-14 | -$94.00K derived: sum of 2 quarters · filed 2025-05-14 | -$45.00K derived: sum of 3 quarters · filed 2025-05-14 | -$181.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$47.00K derived: sum of 2 quarters · filed 2025-03-28 | -$183.00K derived: sum of 3 quarters · filed 2025-03-28 | -$104.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$87.00K derived: sum of 2 quarters · filed 2024-11-12 | -$8.00K 10-Q · filed 2024-11-12 | $34.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$57.00K 10-Q · filed 2024-08-13 | -$15.00K derived: sum of 3 quarters · filed 2024-08-13 | -$41.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $79.00K 10-Q · filed 2024-05-10 | $121.00K derived: sum of 2 quarters · filed 2024-05-10 | $95.00K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $16.00K derived: sum of 2 quarters · filed 2024-02-20 | $60.00K 10-K · filed 2024-02-20 | |
| 2022-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $18.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $44.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |